Revenue rose 21.28% year-over-year to ¥2.04 billion, with net profit up 1.92% and strong growth in innovative drugs and medical devices. R&D investment remained high, and the company advanced multiple late-stage pipeline assets.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.